US 12,084,659 B2
Modulatory polynucleotides
Dinah Wen-Yee Sah, Hopkinton, MA (US); Jinzhao Hou, Lexington, MA (US); and Mathieu Nonnenmacher, Boston, MA (US)
Assigned to VOYAGER THERAPEUTICS, INC., Lexington, MA (US)
Filed by VOYAGER THERAPEUTICS, INC., Lexington, MA (US)
Filed on Nov. 4, 2021, as Appl. No. 17/519,126.
Application 17/519,126 is a continuation of application No. 16/749,293, filed on Jan. 22, 2020, granted, now 11,193,129, issued on Dec. 7, 2021.
Application 16/749,293 is a continuation of application No. 16/302,146, granted, now 10,584,337, issued on Mar. 10, 2020, previously published as PCT/US2017/033268, filed on May 18, 2017.
Claims priority of provisional application 62/485,050, filed on Apr. 13, 2017.
Claims priority of provisional application 62/338,137, filed on May 18, 2016.
Prior Publication US 2022/0162609 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01)
CPC C12N 15/113 (2013.01) [C12N 15/111 (2013.01); C12N 15/85 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/3519 (2013.01); C12N 2310/531 (2013.01); C12N 2310/533 (2013.01); C12N 2320/52 (2013.01); C12N 2750/14143 (2013.01)] 24 Claims
 
1. A modulatory polynucleotide comprising:
(a) a 5′ flanking region comprising the nucleotide sequence of any one of SEQ ID NOs: 1-9;
(b) a loop region comprising the nucleotide sequence of any one of SEQ ID NOs: 10-19; and
(c) a 3′ flanking region comprising the nucleotide sequence of any one of SEQ ID NOs: 20-22, or 24-27.